Cost-Effectiveness of COVID-19 Sequential Vaccination Strategies in Inactivated Vaccinated Individuals in China

Yaqun Fu 1,†, Jingyu Zhao 1,†, Xia Wei 2,†, Peien Han 1, Li Yang 1,*, Tao Ren 1, Siyan Zhan 1 and Liming Li 1,3,*

1 School of Public Health, Peking University, Beijing 100191, China
2 London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK
3 Peking University Center for Public Health and Epidemic Preparedness and Response, Beijing 100191, China
* Correspondence: lyang@bjmu.edu.cn (L.Y.); lmlee@vip.163.com (L.L.)
† These authors contributed equally to this work.

Abstract: To effectively prevent and control the COVID-19 pandemic, countries have adopted a booster vaccination strategy. This study aimed to estimate the cost-effectiveness of sequential booster COVID-19 vaccination compared to two-dose inactivated vaccination in China from a societal perspective. A Markov model was developed to estimate the cost-effectiveness of sequential vaccination, including two doses of an inactivated vaccine followed by a booster shot of an inactivated vaccine, adenovirus vectored vaccine, protein subunit vaccine, or mRNA vaccine. The incremental effects of a booster shot with an inactivated vaccine, protein subunit vaccine, adenovirus vectored vaccine, and mRNA vaccine were 0.0075, 0.0110, 0.0208, and 0.0249 QALYs and saved costs of US$163.96, US$261.73, US$583.21, and US$724.49, respectively. Under the Omicron virus pandemic, the sequential vaccination among adults and the elderly (aged 60–69, 70–79, over 80) was consistently cost-saving, and a booster shot of the mRNA vaccine was more cost-saving. The results indicate that the sequential vaccination strategy is cost-effective in addressing the COVID-19 pandemic, and improving vaccination coverage among the elderly is of great importance in avoiding severe cases and deaths.

Keywords: COVID-19; booster; sequential vaccination; cost-effectiveness; Markov model

1. Introduction

Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which was announced as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 and characterized as a pandemic on 11 March 2020 by the World Health Organization (WHO). It is a serious crisis and severe test for the world and has had a huge impact on the global economy. As of 19 August 2022, the WHO reported approximately 591.68 million cumulative cases and 6.44 million cumulative deaths worldwide [1].

A vast majority of countries have provided vaccinations to safeguard the population and economy throughout the pandemic. A regular vaccination strategy was proven to be cost-saving [2–4] and cost-effective [5,6] in both high-income countries (HICs) and in low- and middle-income countries (LMICs) [7,8]. However, with the variation in viruses across the globe and the waning vaccine effectiveness (VE) against viruses providing booster vaccination to fully vaccinated populations have been considered in many countries. It was found that the effectiveness of the vaccine decreased over time [9]. Although antibodies can be detected after one year of two-dose vaccination, the level decreased dramatically [10]. Internationally, clinical trials have evaluated the safety and efficacy of a booster dose against different virus strains [11–16], and real-world studies have also shown that people with a booster dose have a lower infection rate, hospitalization rate, critical rate, and mortality [17–19].
In this study, sequential vaccination refers to a booster dose that differs from an inactivated vaccine, and homogeneous booster vaccination refers to a booster dose of an inactivated vaccine. A booster dose of a heterogeneous type of vaccine was adopted in some countries as a way to address insufficient vaccination supply, which was found to be safer with better immunogenicity, more efficacy, and more flexibility compared with the homogenous booster [20]. This finding was supported by an increasing number of clinical trials and real-world evidence (RWE). In conclusion, sequential vaccination, both with a homogeneous booster [12,14–16,19,21,22] and a heterogeneous booster [20,23–29], was proven to be more effective and safer than the initial inoculations. However, scarce evidence exists about the cost-effectiveness of booster vaccinations, and there are only limited data about the effects among elderly individuals. Most notably, while the Omicron strain of the virus is currently dominating the pandemic, completing the whole population booster vaccination is of greater urgency, especially among vulnerable groups.

China has offered free vaccination to cover the whole population since January 2021. The first step was to cover people aged 18–59, gradually extending to those aged over 60 in April 2021, to adolescents aged 12–17 in July 2021, and to children aged 3–11 in November 2021. Since then, the government has provided booster vaccination since October 2021 and sequential vaccination since February 2022. As the market share of inactivated vaccines (Sinovac CoronaVac and BBIBP-CorV) in China is approximately 90%, this study only explored the cost-effectiveness of a booster shot with an inactivated vaccine, adenovirus vectored vaccine, protein subunit vaccine, or mRNA vaccine among the two-dose inactivated vaccinated population. Except for the mRNA vaccine, all other types of COVID-19 vaccines are approved for listing in China. We aimed to provide scientific evidence for policymakers to determine the most cost-effective vaccination strategy, to identify whether elderly individuals should be prioritized, to provide economic evidence for its scale-up in the Chinese setting, and to provide suggestions on the marketing and supply of vaccines.

2. Methods

2.1. Study Design

A decision-analytic Markov model using the susceptible–infectious–recovered (SIR) structure was developed to evaluate the cost-effectiveness of sequential vaccination compared with two-dose inactivated vaccination in China from a societal perspective. Base case and scenario analyses were performed to examine the situations stratified by virus strain and age, and sensitivity analyses were conducted to test the robustness of the model.

2.2. Target Population and Vaccination Strategies

The target population of our model was adults aged 18 to 59 who had completed two-dose COVID-19 inactivated vaccination and were eligible for a sequential booster shot in China. We included four types of COVID-19 vaccines, and five vaccination strategies in total: the two-dose inactivated vaccine; booster vaccination with inactivated vaccine, adenovirus vectored vaccine, protein subunit vaccine, and mRNA vaccine (Figure 1A).

2.3. Model Structure and Assumptions

We constructed a model to stimulate the transition of the COVID-19 pandemic over a one-year time horizon, with a weekly cycle. Using a unidirectional SIR structure, six mutually exclusive health statuses were included (Figure 1B). We assumed that all target populations were susceptible to COVID-19 [30], so all participants were in the susceptible status when entering the model. Then, a proportion of them would become infected (I) if exposed to the virus. The infected state was further divided into three separate statuses: I1 denoted infection cases with mild or moderate symptoms; I2 denoted severe cases requiring hospitalization; and I3 denoted critical cases requiring intensive care unit (ICU) care [31]. Patients who survived infection went into the recovered state (R). Patients in I2 or I3 may die.
due to COVID-19 infection, and background mortality was not considered in the one-year time horizon. The model was developed using TreeAge Pro 2021.

The key assumptions of this study were as follows [32]: (1) the same distribution of COVID-19 outcomes across the target population; (2) no spontaneous elimination of the virus; (3) no influence of other nonpharmaceutical interventions (NPIs) on the transition of the disease; (4) all infected individuals would receive treatment; (5) individuals who recovered from COVID-19 infection would not relapse in the study period; (6) non-COVID-19 deaths were ignored during the study period; (7) asymptomatic individuals were included in the infected status and would be static until they recovered; and (8) the vaccination rate was 100% among different age groups in our base case and scenario analysis.

2.4. Model Parameters

2.4.1. Vaccine Effectiveness

The effectiveness of two-dose inactivated vaccination was derived from a real-world study in Chile [33]. The effectiveness of a booster dose with an inactivated vaccine, adenovirus vectored vaccine, and mRNA vaccine came from an observational study in Chile [34]. Since there were no VE data of a booster dose with protein subunit vaccine, we calculated it based on the VE of full inoculation of protein subunit vaccine [35] and mRNA vaccine [36].

2.4.2. Transition Probabilities

The natural infection rate of unvaccinated people was taken from a Chile real-world study (Table 1) [33]. The one-year probability of infection was converted by the incidence in the cohort by $p = 1 - e^{-r}$, where $p$ is the one-year infection probability and $r$ is the incidence rate (person-year) [8]. The transition probabilities between $I_1$, $I_2$, and $I_3$ were obtained from the patient proportion in China [37]. The probability of recovery from different infection statuses came from a study using surveillance data of Chinese and American COVID-19 cases of the original strain [3].

---

**Figure 1.** Decision-analytical Markov model using a susceptible–infectious–recovered (SIR) structure. (A) Decision-analytical Markov model; (B) Susceptible-Infected-Recovered (SIR) structure.
2.4.3. Costs

The societal perspective was adopted with both direct and indirect costs being included in this study, and all costs were converted to US$ using the official exchange rates of 2021 (US$1 = ¥6.449) [38] (Table 1). Cost and QALYs were not discounted due to the one-year time horizon.

The direct medical costs consisted of vaccination costs and medical costs. For the vaccination costs, vaccine procurement, cold-chain transportation, refrigeration, and administration were included. The price of vaccines equalled the lowest global purchase price published by the WHO [39] or news [40]. The transportation cost of the vaccine was assumed to be 6% of the purchase price [41]. The refrigeration cost of inactivated vaccine, adenovirus vectored vaccine, and protein subunit vaccine was calculated at US$0.18 [8], while the cost for the mRNA vaccine was higher at US$0.39 because it needs to be stored in the −70 °C incubator. The vaccine administration fee was US$1.55 per dose [42]. The medical costs covered diagnosis, treatment, hospitalization, and care expenditures, and increased as disease severity grew [43].

Indirect costs came from productivity losses and were calculated based on the average daily salary [44] and working time lost.

2.4.4. Health Utilities

There was a lack of utility scores for different COVID-19 health statuses in the Chinese population. Thus, we used an Iran study focusing on the health utility value of patients with COVID-19, and the utility scores from the Iran population were more representative of the Asian population and covered all health statuses in our model [45]. The utility of people of susceptible statuses was referred to in the paper, focusing on the norms for EQ-5D-5L among the Chinese general population, given that the general population does not have full health [46]. In this paper, we only distinguished the health utilities from the status of disease progression but not from age and sex.

Table 1. Model parameters.

| Parameter                                                       | Base Case Value | Lower Bound | Upper Bound | Distribution | Data Source |
|-----------------------------------------------------------------|-----------------|-------------|-------------|--------------|-------------|
| Vaccination effectiveness (%)                                    |                 |             |             |              |             |
| Two doses of inactivated vaccine                                |                 |             |             |              |             |
| Against infection                                               | 65.90           | 65.20       | 66.60       | Beta         | Jara et al. 2021 [33] |
| Against hospitalization                                         | 87.50           | 86.70       | 88.20       | Beta         |             |
| Against ICU                                                     | 90.30           | 89.10       | 91.40       | Beta         |             |
| Against death                                                   | 86.30           | 84.50       | 87.90       | Beta         |             |
| Two doses of inactivated vaccine + booster shot of inactivated vaccine |                 |             |             |              |             |
| Against infection                                               | 78.80           | 76.80       | 80.60       | Beta         | Jara et al. 2022 [34] |
| Against hospitalization                                         | 86.30           | 83.70       | 88.50       | Beta         |             |
| Against ICU                                                     | 92.20           | 88.70       | 94.60       | Beta         |             |
| Against death                                                   | 86.70           | 80.50       | 91.00       | Beta         |             |
| Two doses of inactivated vaccine+ booster shot of protein subunit vaccine |                 |             |             |              |             |
| Against infection                                               | 83.22           | 74.90       | 91.54       | Beta         | Calculated |
| Against hospitalization                                         | 91.44           | 82.30       | 100         | Beta         |             |
| Against ICU                                                     | 91.63           | 82.47       | 100         | Beta         |             |
| Against death                                                   | 91.64           | 82.48       | 100         | Beta         |             |
| Two doses of inactivated vaccine + booster shot of adenovirus vectored vaccine |                 |             |             |              |             |
| Against infection                                               | 93.20           | 92.90       | 93.60       | Beta         | Jara et al. 2022 [34] |
| Against hospitalization                                         | 97.70           | 97.30       | 98.00       | Beta         |             |
| Against ICU                                                     | 98.90           | 98.30       | 99.20       | Beta         |             |
| Against death                                                   | 98.10           | 97.30       | 98.60       | Beta         |             |
| Two doses of inactivated vaccine+ booster shot of mRNA vaccine   |                 |             |             |              |             |
| Against infection                                               | 96.50           | 96.20       | 96.70       | Beta         | Jara et al. 2022 [34] |
| Against hospitalization                                         | 96.10           | 95.30       | 96.90       | Beta         |             |
| Against ICU                                                     | 96.20           | 94.60       | 97.30       | Beta         |             |
| Against death                                                   | 96.80           | 93.90       | 98.30       | Beta         |             |
Table 1. Cont.

| Parameter                                      | Base Case Value | Lower Bound | Upper Bound | Distribution | Data Source                      |
|------------------------------------------------|-----------------|-------------|-------------|--------------|----------------------------------|
| Transition probabilities without vaccination   |                 |             |             |              |                                  |
| Natural infection rate                         | 0.1043          | 0.0939      | 0.1147      | Beta         | Jara et al. 2021 [33]            |
| I₂ to I₃                                       | 0.1450          | 0.1305      | 0.1595      | Beta         |                                  |
| I₃ to death                                    | 0.2540          | 0.2286      | 0.2794      | Beta         | Zhao et al. 2021 [37]            |
| I₂ to death                                    | 0.0005          | 0.00045     | 0.00055     | Beta         |                                  |
| I₃ to death                                    | 0.0005          | 0.00045     | 0.00055     | Beta         |                                  |
| I₁ to recover                                  | 0.7475          | 0.6728      | 0.8223      | Beta         | Padula et al. 2021 [3]           |
| I₂ to recover                                  | 0.6500          | 0.5850      | 0.7150      | Beta         |                                  |
| I₃ to recover                                  | 0.5300          | 0.4770      | 0.5830      | Beta         |                                  |
| Vaccination cost per dose (2021 USD)           |                 |             |             |              |                                  |
| Inactivated vaccine                            | 4.00            | 4.00        | 5.50        | Gamma        | WHO [39]; Calculated             |
| Adenovirus vectored vaccine                    | 15.00           | 9.63        | 15.00       | Gamma        | WHO [39]; Calculated             |
| Protein subunit vaccine                        | 19.54           | 2.12        | 19.54       | Gamma        | News [40]; Calculated            |
| mRNA vaccine                                   | 6.75            | 3.80        | 6.75        | Gamma        | WHO [39]; Calculated             |
| Cold-chain freight fee as a percentage of vaccine cost | 6%             | /           | /           | /            | Chen et al. 2019 [41]            |
| Refrigerator storage of 2–8 °C incubator       | 0.18            | /           | /           | /            | Jiang et al. 2022 [8]            |
| Refrigerator storage of −70 °C incubator       | 0.39            | /           | /           | /            | Calculated                       |
| Administration                                 | 1.55            | /           | /           | /            | National medical insurance bureau [42] |
| Medical costs of health status (2021USD)       |                 |             |             |              |                                  |
| I₁                                             | 876.32          | 619.11      | 1804.12     | Gamma        | Jin et al. 2020 [43]             |
| I₂                                             | 8284.63         | 5852.95     | 17057.25    | Gamma        | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| I₃/Death                                       | 23469.03        | 16861.36    | 49139.19    | Gamma        | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| Length of hospital stay (day)                  |                 |             |             |              |                                  |
| I₁                                             | 14              | /           | /           | /            | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| I₂                                             | 21              | /           | /           | /            | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| I₃                                             | 42              | /           | /           | /            | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| Death                                          | 42              | /           | /           | /            | Jin et al. 2020 [43]; Zhao et al. 2021 [37] |
| Average salary per day (2021USD)               | 42.55           | 32.07       | 76.04       | Gamma        | National Bureau of Statistics [44] |

Health utilities

| Susceptible                                    | 0.946           | 0.9461      | 1           |              | Xie et al. 2022                  |
| I₁                                             | 0.847           | 0.762       | 0.932       | Beta         |                                  |
| I₂                                             | 0.766           | 0.689       | 0.843       | Beta         |                                  |
| I₃                                             | 0.629           | 0.566       | 0.692       | Beta         | Alinia et al. 2021 [45]          |
| Recover                                        | 0.896           | 0.806       | 0.986       | Beta         |                                  |
| Death                                          | 0               | /           | /           | /            |                                  |

2.5. Model Analysis
2.5.1. Base Case Analysis

The total costs and quality-adjusted life years (QALYs) were generated for each vaccination strategy, and then the incremental cost-effectiveness ratio (ICER) was calculated. It was compared with the willingness-to-pay (WTP) threshold of the gross domestic product (GDP) per capita of China in 2021 (US$ 12556.37) [44] to determine whether the booster vaccination strategy was cost-effective and which combination was the most cost-effective strategy. When there were dominant strategies, net monetary benefit (NMB) was evaluated instead.

Although WTP may vary with educational level, place of residence, and attitude towards disease, we still used a fixed threshold as commonly used in other studies [47]. In addition, we did not apply willingness-to-accept [48] in this study as we adopted a societal perspective, and no vaccination-related payments were required in the Chinese setting.
2.5.2. Sensitivity Analysis

One-way sensitivity analysis and probabilistic sensitivity analysis (PSA) were performed to explore the robustness of the model. In the one-way sensitivity analysis, all cost parameters were varied by their 95% confidence interval, a specific range where available, or ±10% of the point estimated value. For the cost of vaccine per dose, we assumed the health insurance paid for the same price for a full vaccination procedure for different kinds of vaccines, and used this cost as the lower bound for different vaccines.

For PSA, Monte Carlo simulation (N = 1000 iterations) was used to assess the effects of changing multiple parameters simultaneously. Cost parameters were assumed to follow gamma distributions, and utilities, probabilities, and rates were assumed to follow beta distributions. The results were presented as cost-effectiveness acceptability curves to demonstrate the probability of being cost-effective for different vaccination strategies at various WTP thresholds.

2.5.3. Scenario Analysis

Scenario analysis was performed to adjust the VE of vaccination under the Omicron strain pandemic and to examine the cost-effectiveness for elderly groups aged 60–69, 70–79, and over 80 years old. In the first scenario, Hong Kong [49,50] and Shanghai [51] real-world data under the Omicron strain pandemic were used to calculate the VE of sequential vaccination and the transition probabilities between each health status. The parameters for the Hong Kong situation are listed in Supplementary Materials Table S1, and those for the Shanghai situation are listed in Table S2. In the second scenario, the targeted population was adults aged over 60, and the VE among people aged over 60 and mortality of the elderly among different age groups (60–69, 70–79, 80+) were generated using Hong Kong real-world data [50,52] (Table S3).

3. Results

3.1. Base Case Analysis

Sequential vaccination after a two-dose inactivated COVID-19 vaccine with different types of booster doses generated more QALYs with lower costs and thus was cost-saving compared with the two-dose inactivated vaccine group. Moreover, the heterogeneous vaccination groups reduced the number of infection cases with lower costs compared with the homogeneous group. More precisely, compared with two-dose vaccination, a booster with an inactivated vaccine, protein subunit vaccine, adenovirus vectored vaccine, and mRNA vaccine increased 0.0075, 0.0110, 0.0208, and 0.0249 QALYs and saved US$163.96, US$261.73, US$583.21, and US$724.49, respectively (Table 2).

| Strategy | Cost (US$) | Effect (QALYs) | NMB (US$) | Incremental Cost (US$) | Incremental Effect (QALYs) | ICER (US$/QALY) |
|----------|------------|----------------|-----------|------------------------|---------------------------|------------------|
| Two-dose inactivated vaccine | 918.26 | 0.9062 | 9188.22 | - | - | - |
| Two doses of inactivated vaccine+ booster shot of inactivated vaccine | 755.30 | 0.9138 | 9435.36 | -162.96 | 0.0075 | -21,587.61 |
| Two doses of inactivated vaccine+ booster shot of protein subunit vaccine | 656.52 | 0.9172 | 9572.21 | -261.73 | 0.0110 | -23,875.83 |
| Two doses of inactivated vaccine+ booster shot of adenovirus vectored vaccine | 335.04 | 0.9271 | 10,003.44 | -583.21 | 0.0208 | -26,034.30 |
| Two doses of inactivated vaccine+ booster shot of mRNA vaccine | 193.77 | 0.9311 | 10,190.13 | -724.49 | 0.0249 | -29,123.71 |
3.2. Sensitivity Analysis

The model results were robust, and the sequential vaccination strategy was always cost-saving under parameter variation. Cost parameters influenced the model more than effectiveness parameters (Figure S1). In addition, sensitivity analyses of NMB were generated to determine the top ten factors that influenced the model most, with utility for susceptible cases, the utility of recovered cases, and medical cost for mild/moderate cases ranked in the top three (Figure 2).

![Net Monetary Benefits](image)

**Figure 2.** One-way sensitivity analyses of net monetary benefit for the model on willingness to pay.

In the PSA, since all sequential vaccination strategies were cost-saving compared with two-dose vaccination and a booster with mRNA vaccine can increase more QALYs at the lowest price, the probability for the sequential vaccination strategy using the mRNA vaccine as a booster shot being cost-effective was 100% compared with the other vaccination strategies (Figure 3).

3.3. Scenario Analysis

The results in scenario one showed that the total cost increased when the Omicron strain dominated the pandemic, and the booster vaccination strategy remained cost-saving. A booster of the mRNA vaccine could increase more QALYs at the lowest price (Tables S4 and S5). Specifically, booster vaccination strategies in Hong Kong could save costs ranging from US$61.62 to US$99.95 and increase QALYs from 0.0046 to 0.0073. Meanwhile, for the situation in Shanghai, a booster vaccination could save costs ranging from US$14.83 to US$46.69 and increase QALYs from 0.0004 to 0.0011.
Figure 3. Cost-effectiveness acceptability curve.

For scenario two, vaccination strategies remained effective and cost-saving in different age groups (60–69, 70–79, 80+) (Table S6). Labor loss due to illness was excluded from the model, and the total cost declined. The results indicated that increasing the coverage of booster vaccination among elderly people, especially octogenarians, dramatically decreased total costs. Hong Kong data illustrated that the percentage of severe disease and death increased dramatically with age among the elderly population without or with incomplete vaccination. Our results have shown that it is of great importance to provide sequential vaccination to elderly individuals, as the effectiveness of sequential vaccination strategies was proven to increase with age.

4. Discussion

This study developed an SIR status-adapted Markov model, and our analysis suggested that sequential vaccination was more effective at a lower cost than two-dose inactivated vaccination regardless of the type of booster dose. The findings are consistent with current prevention and control strategies in China and can provide crucial evidence to support decision-making.

The Markov model has been widely used to examine the cost-effectiveness of vaccination worldwide [3,4,52]. Although SIR or susceptible–exposed–infectious–recovered (SEIR) statuses were also adopted in their models, the effectiveness rate, the coverage rate, or the vaccine prices were assumed due to a lack of data. In addition, the assumption in our model that only patients with severe and critical diseases will die was much more reasonable than a previous study [4]. Our model included more comprehensive parameters and the latest data generated from real-world studies in the Chinese setting. To the best of our knowledge, this is the first cost-effectiveness analysis of COVID-19 sequential vaccination, and our results indicate that the sequential vaccination strategy is cost-saving compared with the two-dose vaccination.

By 7 September 2022, China reported 3433.96 million doses of COVID-19 vaccine, and 1270.66 million people have completed the initial inoculation, covering 90.13% of the total population; 8570.50 million people have received a booster shot, among which 45.72 million have competed for sequential vaccination [53]. Recently, the Omicron strain has become the most influential virus strain and has brought a huge burden to the world. The RWE from Hong Kong shows that people with incomplete vaccine inoculation or without vaccination accounted for 88.3% of total deaths, and most of the deceased cases were unvaccinated persons, especially the elderly [50]. Although VE against the Omicron strain was less...
effective than against other variants \cite{18,25,54–56}, RWE shows that homogeneous booster vaccination still has a very high-level protection rate, with VE against severe disease and death from approximately 92% \cite{57} to 98% \cite{49}. Although the pandemic patterns of Hong Kong and Shanghai are different, full inoculation and booster vaccination have been proven to be efficient in decreasing severe cases and deaths in a real-world setting, and our study can provide compelling cost-effectiveness evidence to support the sequential vaccination strategy, even when the Omicron strain dominated the pandemic.

Regarding the vaccination situation of the elderly in China, 227.44 million people aged over 60 years old completed the initial inoculation, reaching 86.14%, but only half of them received a booster dose of the COVID-19 vaccine \cite{53}. They are more vulnerable but have relatively lower vaccination coverage, which may lead to an enormous risk of severe cases and deaths emerging under the Omicron pandemic. In this study, sequential vaccination strategies among different age groups were consistently effective and cost-saving, and adhering to and increasing the vaccination coverage rate with a booster dose should be encouraged to protect the elderly population. As this study would like to explore the cost-effectiveness of universal booster vaccination, the 100% coverage rate may slightly overestimate the effects of vaccination. The conclusion of this study was consistent with and supported by a recently published American study, which concluded that the booster vaccination strategy among elderly individuals was cost-saving compared to the two-dose mRNA vaccine without a booster \cite{58}.

Moreover, implementing a sequential vaccination strategy that gives priority to mRNA vaccines, adenovirus vectored vaccines and protein subunit vaccines and improves the vaccination coverage rate among elderly individuals, especially the rate of booster vaccination, is of great importance and is an effective way to prevent the outbreak of severe cases and deaths under the Omicron pandemic.

Our study has also shown that a booster shot of mRNA vaccines can increase more QALYs at the lowest price. Since mRNA vaccines are still unavailable in mainland China, the importation of mRNA vaccines or the marketing approval process of domestic mRNA vaccines should be accelerated. The price of mRNA used in our study can also be used as a reference for pricing.

The control of the Omicron strain pandemic has faced huge challenges. Further research on the exploration of the most cost-effective combination of vaccines and different NPI strategies in real-world scenarios, the reduction of unnecessary lockdown and containment policies, and the maximization of smooth society operation and economic development are needed to guarantee economic development, the sustainability of the health system, and to safeguard population well-being.

This study has some limitations. First, the medical costs of infected cases were obtained from the early stage of the COVID-19 outbreak in Wuhan, China. These data may change as the pandemic progresses, the diagnosis and treatment guidelines improve, and the infectivity and pathogenicity of the virus change. However, the Wuhan study contains the most complete and robust data on medical costs. Second, the transition probabilities between different health statuses were calculated using Hong Kong RWE; however, since mass testing of COVID-19 was not adopted there, the infection rate was underestimated, as asymptomatic cases could not be identified. Third, the SIR model cannot simulate the status from recovered to infected again, while in real-world settings, being recovered from COVID-19 can result in reinfection with another virus variant. A further limitation is that the simulation period was only one year, without considering the waning of effectiveness, since the adoption of the booster vaccination strategy lasted less than one year, and the evidence on the process and rates of the waning of effectiveness was lacking. Further analysis for a longer period considering the waning of vaccine effectiveness and mutating of virus strains is needed. Finally, due to the unavailability of the proportion of asymptomatic status, this study was not able to distinguish it from infected status.
5. Conclusions

The sequential vaccination strategy is cost-saving regardless of the type of vaccine in China as a real-world setting, and implementing the sequential vaccination of booster shots with heterogeneous vaccines can be given priority, in which a booster shot of mRNA vaccines is the most cost-saving strategy. Under the circumstances of the Omicron pandemic, improving the vaccination coverage rate among the elderly is of great importance in avoiding severe cases and deaths.

6. Patents

No patients or the public were involved in this study.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines10101712/s1, Figure S1: One-way sensitivity analyses for the model on ICER(US$/QALYs); Table S1: Model parameters under the Omicron strain pandemic; Table S2: Model parameters for people aged over 60 under the Omicron strain pandemic; Table S3: Cost-effectiveness analysis of different sequential vaccination strategies compared with initial inoculation under the Omicron strain pandemic; Table S4: Cost-effectiveness analysis of different sequential vaccination strategies among age-specific groups.

Author Contributions: L.Y. conceived this analysis article. Y.F. and J.Z. collected the evidence and drafted the manuscript. L.Y., X.W. and P.H. reviewed and edited the manuscript. L.Y., T.R., S.Z. and L.L. coordinated the overall process. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants from the National Natural Science Foundation of China [72174010], Natural Science Foundation of Beijing Municipality [M22033], and Capital Health Research and Development of Special Fund [2021-1G-4091].

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments: The authors thank the China National Biotec Group for data support.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

1. World Health Organization (WHO). Coronavirus COVID-19 Dashboard. Available online: https://covid19.who.int (accessed on 8 December 2021).
2. Shaker, M.; Abrams, E.M.; Greenhawt, M. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies. J. Allergy Clin. Immunol. Pract. 2021, 9, 2658–2668.e3. [CrossRef] [PubMed]
3. Padula, W.V.; Malaviya, S.; Reid, N.M.; Cohen, B.G.; Chingcuanco, F.; Ballreich, J.; Tierce, J.; Alexander, G.C. Economic value of vaccines to address the COVID-19 pandemic: A U.S. cost-effectiveness and budget impact analysis. J. Med. Econ. 2021, 24, 1060–1069. [CrossRef] [PubMed]
4. Kohli, M.; Maschio, M.; Becker, D.; Weinstein, M.C. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine 2021, 39, 1157–1164. [CrossRef] [PubMed]
5. Marco-Franco, J.E.; Emilio, J.; Pita-Barros, P.; González-de-Julián, S.; Sabat, I.; Vivas-Consuelo, D. Simplified Mathematical Modeling of Uncertainty: Cost-Effectiveness of COVID-19 Vaccines in Spain. Mathematics 2021, 9, 566. [CrossRef]
6. Debrabant, K.; Grenbaek, L.; Kronborg, C. The Cost-Effectiveness of a COVID-19 Vaccine in a Danish Context. Clin. Drug Invest. 2021, 41, 975–988. [CrossRef]
7. Hagens, A.; Inkaya, A.; Yildirak, K.; Sancar, M.; van der Schans, J.; Sancar, A.A.; Ünal, S.; Postma, M.; Yeşenoglu, S. COVID-19 Vaccination Scenarios: A Cost-Effectiveness Analysis for Turkey. Vaccines 2021, 9, 399. [CrossRef]
8. Jiang, Y.; Cai, D.; Shi, S. Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions: A modeling study. *Infect. Dis. Model.* 2021, 7, 109–121. [CrossRef] [PubMed]

9. Belayachi, J.; Obtel, M.; Razine, R.; Abouqal, R. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco. *medRxiv* 2022. [CrossRef]

10. Göckner, S.; Hornung, F.; Baier, M.; Weis, S.; Pletz, M.W.; Deinhardt-Emmer, S.; Lößler, B. CoNAN Study Group Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection. *Viruses* 2021, 13, 2003. [CrossRef]

11. Levine-Tiefenbrun, M.; Yelin, I.; Alapi, H.; Katz, R.; Herzel, E.; Chodick, G.; Gazit, S.; Patalon, T.; Kishony, R. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. *Nat. Med.* 2021, 27, 2108–2110. [CrossRef]

12. Zeng, G.; Wu, Q.; Pan, H.; Li, M.; Yang, J.; Wang, L.; Wu, Z.; Jiang, D.; Deng, X.; Chu, K.; et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. *Lancet Infect. Dis.* 2021, 22, 483–495. [CrossRef]

13. Abbasi, J. Studies Suggest COVID-19 Vaccine Boosters Save Lives. *JAMA* 2022, 327, 115. [CrossRef] [PubMed]

14. Guo, W.; Duan, K.; Zhang, Y.; Yuan, Z.; Zhang, Y.; Wang, Z.; Zhao, D.; Zhang, H.; Xie, Z.; Li, X.; et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A ran-domized, double-blind, placebo-controlled, phase 1/2 trial. *cClinicalMedicine* 2021, 38, 101010. [CrossRef] [PubMed]

15. Pan, H.; Wu, Q.; Zeng, G.; Yang, J.; Jiang, D.; Deng, X.; Chu, K.; Zheng, W.; Zhu, F.; Yu, H.; et al. Immunogenicity and safety of a third dose, and immune persistence of CoronaVac in healthy adults aged 18–59 years: Interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial. *medRxiv* 2021. [CrossRef]

16. Falsey, A.R.; Frenck, R.W., Jr.; Walsh, E.E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Bailey, R.; Swanson, K.A.; Xu, X.; et al. Immunogenicity and safety of SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. *N. Engl. J. Med.* 2021, 385, 1627–1629. [CrossRef]

17. Saban, M.; Myers, V.; Wilf-Miron, R. Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 vari-ant ten months into the vaccination program: The Israeli case. *Prev. Med.* 2022, 154, 106890. [CrossRef]

18. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. *N. Engl. J. Med.* 2022, 385, 1393–1400. [CrossRef] [PubMed]

19. Barda, N.; Dagan, N.; Cohen, C.; Hernán, M.A.; Lipsitch, M.; Kohane, I.S.; Reis, B.Y.; Balicer, R.D. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. *Lancet* 2021, 398, 2093–2100. [CrossRef]

20. Sapkota, B.; Saud, B.; Shrestha, R.; Al-Fahad, D.; Sah, R.; Shrestha, S.; Rodriguez-Morales, A.J. Heterologous prime–boost strategies for COVID-19 vaccines. *J. Travel Med.* 2021, 29, taab191. [CrossRef]

21. Petrelli, F.; Luciani, A.; Borgonovo, K.; Ghilardi, M.; Parati, M.C.; Petrò, D.; Lonati, V.; Pesenti, A.; Cabiddu, M. Third dose of SARS-CoV-2 vaccine: A systematic review of 30 published studies. *J. Med. Virol.* 2022, 94, 2837–2844. [CrossRef]

22. Thompson, M.G. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance-VI-NION Network, 10 States, August 2021-January 2022. *MMWR Morb. Mortal. Wkly. Rep.* 2022, 71, 139–145. [PubMed]

23. Hillus, D.; Schwarz, T.; Tober-Lau, P.; Vanshylla, K.; Hastor, H.; Thibeault, C.; Jentzsch, S.; Helbig, E.T.; Lippert, L.J.; Tscheak, P.; et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1/mRNA-1273 vaccination. *Science* 2021, 375, 807–810. [CrossRef]

24. Kaku, C.I.; Champney, E.R.; Normark, J.; Garcia, M.; Johnson, C.E.; Ahlm, C.; Christ, W.; Sakkharak, M.; Ackerman, M.E.; Klingström, J.; et al. Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination. *Science* 2022, 375, 1041–1047. [CrossRef]
30. Commission, N.H. COVID-19 Diagnosis and Treatment Guideline (Version 9). Available online: http://www.nhc.gov.cn/yzygj/s7653p/202203/b74a4de1baa449458805a3d3e40093d88.shtml (accessed on 30 March 2022).

31. China, M.o.T.o.P.s.R.o. COVID-19 Prevention and Control Guidelines for Ports and Their Frontline Personnel (Ninth Edition). Available online: https://xsgk.mot.gov.cn/2020/jigou/sj/202203/120220303_3644120.html (accessed on 24 March 2022).

32. Zhou, D.; Shao, T.; Shao, H.; Tu, Y.; Tang, Y.; Zhou, J.; Malone, D.; Tang, W. EPH172 When Is It Valuable for COVID-19 Booster Dose?: A Transmission Dynamics Model-Based Effectiveness and Cost-Effectiveness Analysis of Two Booster Dose Vaccination Priority Strategies in Mainland China. Value Health 2022, 25, 5466. [CrossRef]

33. Jara, A.; Undurraga, E.A.; González, C.; Faredes, F.; Fontecilla, T.; Jara, G.; Araos, R. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N. Engl. J. Med. 2021, 385, 875–884. [CrossRef]

34. Jara, A.; Undurraga, E.A.; Zubizarreta, J.R.; González, C.; Pizarro, A.; Acevedo, J.; Araos, R. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: A large-scale pro-prospective cohort study. Lancet Glob. Health 2022, 10, e798–e806. [CrossRef]

35. Zhifei Biological Products Co., L. The Coronavirus Recombinant Protein Vaccine (CHO Cells) has been Approved for Conditional Marketing. Available online: http://www.zhifeishengwu.com/news/gsyw/qyyw/2022-03-02/624.html (accessed on 21 March 2022).

36. Zheng, C.; Shao, W.; Chen, X.; Zhang, B.; Wang, G.; Zhang, W. Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis. Int. J. Infect. Dis. 2021, 114, 252–260. [CrossRef] [PubMed]

37. Zhao, J.; Jin, H.; Li, X.; Jia, J.; Zhang, C.; Zhao, H.; Ma, W.; Wang, Z.; He, Y.; Lee, J.; et al. Disease Burden Attributable to the First Wave of COVID-19 in China and the Effect of Timing on the Cost-Effectiveness of Movement Restriction Policies. Value Health 2021, 24, 615–624. [CrossRef]

38. Data, O. Exchange Rates. 2022. Available online: https://data.oecd.org/conversion/exchange-rates.htm (accessed on 10 April 2022).

39. World Health Organization. Vaccine Purchase Data. Available online: https://www.who.int/teams/immunization-vaccines-and-biologicals/vaccine-access/m4a4/m4a4-vaccine-purchase-data (accessed on 20 February 2022).

40. Finance, S. In-depth Analysis of the Pharmaceutical Industry. Available online: http://stock.finance.sina.com.cn/stock/go.php/vReport_Show/kind/lastest/rptid/660793064184/index.php (accessed on 5 April 2022).

41. Chen, C.; Liceras, F.C.; Flasche, S.; Sidharta, S.; Yoong, J.; Sundaram, N.; Jit, M. Effect and cost-effectiveness of pneumococcal conjugate vaccination: A global modelling analysis. Lancet Glob. Health 2019, 7, e86–e87. [CrossRef]

42. Bureau, N.M.I. Notice on the Effective Implementation of Phased Liquidation of Coronavirus Vaccines and Vaccination Costs. Available online: http://www.nhsa.gov.cn/art/2021/8/23/art_53_5856.html (accessed on 20 February 2022).

43. Jin, H.; Wang, H.; Li, X.; Zheng, W.; Ye, S.; Zhang, S.; Zhou, J.; Pennington, M. Economic burden of COVID-19, China, January-March, 2020: A cost-of-illness study. Bull. World Health Organ. 2021, 99, 112–124. [CrossRef]

44. Statistics, N.B.o. China Statistical Data. Available online: https://data.stats.gov.cn/easyquery.htm?cn=C01 (accessed on 10 April 2022).

45. Alinia, C.; Yaghmaei, S.; Abdullah, F.Z.; Ahmadi, A.; Samadi, N.; Pourteimour, S.; Safari, H.; Mahmoudi, H.; Moradi, G.; Piroozii, B. The health-related quality of life in Iranian patients with COVID-19. BMC Infect. Dis. 2021, 21, 459.

46. Xie, S.; Wu, J.; Xie, F. Population Norms for SF-6Dv2 and EQ-5D-5L in China. Appl. Health Econ. Health Policy 2022, 20, 573–585. [CrossRef] [PubMed]

47. Harapan, H.; Anwar, S.; Bustamam, A.; Radiansyah, A.; Angraini, P.; Fasli, R.; Salwiyadi, S.; Bastian, R.A.; Oktiviaryi, A.; Akmal, I.; et al. Willingness to pay for a dengue vaccine and its associated determinants in Indonesia: A community-based, cross-sectional survey in Aceh. Acta Trop. 2017, 166, 249–256. [CrossRef] [PubMed]

48. Kabir, K.M.A.; Hagishima, A.; Tanimoto, J. Hypothetical assessment of efficiency, willingness-to-accept and willing-ness-to-pay for dengue vaccine and treatment: A contingent valuation survey in Bangladesh. Hum. Vaccin. Immunother. 2021, 17, 773–784. [CrossRef] [PubMed]

49. Kong, T.U.o.H. COVID-19 Vaccine Effectiveness in Hong Kong. Available online: http://www.med.hku.hk/en/news/press/-/media/9DC071B122C54C3089C5319E43E5187C.ashx (accessed on 5 April 2022).

50. Hong Kong Special Administrative Region Government. Archive of Statistics on 5th Wave of COVID-19. Available online: https://www.coronavirus.gov.hk/eng/5th-wave-statistics.html (accessed on 11 April 2022).

51. Department of Health, The Government of the Hong Kong Special Administrative Region. Health Fact of Hong Kong in 2021. Available online: http://www.gov.hk/chs/statistics/statistics_hs/statistics_hfhk.html (accessed on 10 February 2022).

52. Wang, W.-C.; Fann, J.C.-Y.; Chang, R.-E.; Jeng, Y.-C.; Hsu, C.-Y.; Chen, H.-H.; Liu, J.-T.; Yen, A.M.-F. Economic evaluation for mass vaccination against COVID-19. J. Formos. Med. Assoc. 2021, 120, S95–S105. [CrossRef]

53. Council, S. Vaccination Status. Available online: http://www.gov.cn/xinwen/2021-07/content_5589903.htm (accessed on 20 September 2022).

54. Yu, X.; Wei, D.; Xu, W.; Li, Y.; Li, X.; Zhang, X.; Qu, J.; Yang, Z.; Chen, E. Reduced sensitivity of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv 2021. [CrossRef]

55. Angkasekwinai, N.; Niyomnaitham, S.; Sewatanon, J.; Phumiamorn, S.; Sukapirom, K.; Senawong, S.; Toh, Z.Q.; Umrod, P.; Somporn, T.; Chumpol, S.; et al. The immunogenicity and reactivity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series. medRxiv 2022. [CrossRef]

56. Ai, J.; Zhang, H.; Zhang, Y.; Lin, K.; Zhang, Y.; Wu, J.; Wan, Y.; Huang, Y.; Song, J.; Fu, Z.; et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes Infect. 2022, 11, 337–343. [CrossRef] [PubMed]
57. Huang, Z.; Xu, S.; Liu, J.; Wu, L.; Qiu, J.; Wang, N.; Ren, J.; Li, Z.; Guo, X.; Tao, F.; et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 variant infection, severe illness, and death. *medRxiv* 2022. [CrossRef]

58. Li, R.; Liu, H.; Fairley, C.K.; Zou, Z.; Xie, L.; Li, X.; Shen, M.; Li, Y.; Zhang, L. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. *Int. J. Infect. Dis.* 2022, 119, 87–94. [CrossRef]